Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

CAR-NK cell therapy in hematologic malignancies (2019–2025): A systematic review

View Full Paper
Ask AI
Bookmark
Share

Authors

MTMousa Thalji

Discussion

Loading...

Member takes

Overview

Systematic review reports overall response rates between 50-80% in leukemia and lymphoma, indicating CAR-NK cell therapy is a promising option for hematologic malignancies.

Key Points

  • CAR-NK cell therapy induces durable remissions in indolent lymphoma but shorter in aggressive disease, with responses observed lasting around 2-5 months.
  • The review highlights that CAR-NK products were evaluated in eight clinical trials involving leukemia and lymphoma targeting specific antigens.
  • Clinical trials demonstrated favorable safety profiles for CAR-NK therapy, with no cases of graft-versus-host disease reported across the studies.
  • Future trials will focus on enhancing CAR-NK dosing and targeting strategies to improve long-term remission in blood cancers.

Cite This Study

Mousa Thalji (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d413https://doi.org/10.1182/blood-2025-7652
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Beyond CAR-T: The Rise of CAR-NK/T Cells for Haematological Cancer2025 · 5 citations
  2. 2Precision sniper for solid tumors: CAR-NK cell therapy2025 · 15 citations
  3. 3Effiefficacy and safety of allogeneic CD123 CAR-NK cell therapy in Relapsed/Refractory Acute Myeloid Leukemia2025 · 3 citations
  4. 4Exploring CAR cell therapies beyond CAR-T for myeloid malignancies2026 · 1 citations
  5. 5Clinical trials of nanoparticle-enhanced CAR-T and NK cell therapies in oncology: overcoming translational and clinical challenges - a mini review2025 · 16 citations